Newsroom

Sorted by: Latest

-

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. “Throughout the first half of the year, we have remained laser focused on meaningful execution of our three strategic priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profit...
-

Vistance Networks Reports Second Quarter 2026 Results

RICHARDSON, Texas--(BUSINESS WIRE)--Vistance Networks, Inc. (NASDAQ: VISN), a leading provider of intelligent network solutions, reported results for the quarter ended June 30, 2026....
-

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve...
-

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quarter marked a defining moment for Precision BioSciences and the hepatitis B field, with the first clinical biopsy evidence that a therapeutic...
-

Xeris Biopharma Reports Second Quarter 2026 Financial Results

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026. "The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlev’s exceptional commercial momentum,” said John Shannon,...
-

Vital Farms Reports Second Quarter 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its second quarter ended June 28, 2026. Financial highlights for the second quarter ended June 28, 2026, compared to the second quarter ended June 29, 2025, where applicable, include: Net Revenue decreased 10.1% to $166.0 million, compared to $184.8 million Gross Margin of 6.6%, compared to 38.9% Net Loss of $31.1...
-

Vintage Parts Appoints Jim Lyski as Chief Executive Officer

NEW YORK--(BUSINESS WIRE)--Vintage Parts, a leading provider of original equipment manufacturer (OEM)-sourced replacement parts serving customers across North America, and a portfolio company of GenNx360 Capital Partners (“GenNx360”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, today announced the appointment of Jim Lyski as Chief Executive Officer, effective August 1, 2026. Mr. Lyski brings over three deca...
-

PENN Entertainment, Inc. Reports Second Quarter Results

WYOMISSING, Pa.--(BUSINESS WIRE)--PENN Entertainment, Inc. (“PENN” or the “Company”) (Nasdaq: PENN) today reported financial results for the three and six months ended June 30, 2026. Jay Snowden, Chief Executive Officer and President, said: “We continued to execute against our 2026 strategic priorities this quarter: delivering Segment Adjusted EBITDAR growth, optimizing corporate overhead, growing cash flow, and deleveraging the balance sheet. PENN achieved record quarterly Retail segment reven...
-

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. (“Bausch Health”), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the c...
-

BlackSky Reports Second Quarter 2026 Results

HERNDON, Va.--(BUSINESS WIRE)--BlackSky Technology Inc. (“BlackSky” or the “Company”) (NYSE: BKSY) announced results for the second quarter ended June 30, 2026. “Strong sales performance is accelerating revenue and earnings growth, driven by a 50% growth in space-based intelligence services from Q1,” said Brian E. O’Toole, BlackSky CEO. “With the exceptional performance of Gen-3, we’re seeing momentum across all aspects of our business resulting in an expanding customer base, a growing pipeline...